Rein Therapeutics Inc
Research Rein Therapeutics Inc (RNTX) on Bullrun: market cap USD 68.61M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRNTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 68.61M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.84M
- Free cash flow-USD 16.61M
Valuation Snapshot
latest market cap is USD 68.61M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 49.90M | -USD 19.36M | n/a | -1.96 | USD 3.22M | n/a | USD 16.92M |
| FY2024 | USD 0 | -USD 62.90M | -USD 22.29M | n/a | -3.51 | USD 12.87M | USD 0 | USD 54.39M |
| FY2023 | USD 0 | -USD 15.70M | n/a | n/a | -3.42 | USD 17.34M | USD 48.00K | USD 98.30M |
| FY2022 | USD 0 | -USD 27.33M | n/a | n/a | -6.02 | USD 5.19M | n/a | USD 18.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 68.61M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 31.96M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 49.83M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 14.90M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.76M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 50.99M | n/a | n/a | n/a |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rein Therapeutics Inc's market cap?
Rein Therapeutics Inc's market capitalization is USD 68.61M.
What does Rein Therapeutics Inc do?
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.